- Home
- RNA vs ALEC Comparison
RNA vs ALEC Comparison
Compare RNA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | ALEC |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 245.4M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RNA | ALEC |
|---|---|---|
| Price | $11.54 | $1.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | ★ $69.26 | $4.83 |
| AVG Volume (30 Days) | 162.8K | ★ 752.9K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $88.12 | $2.03 |
| Revenue Next Year | $18.11 | $29.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.77 | $1.09 |
| 52 Week High | $73.06 | $3.40 |
Technical Indicators
Market Signals| Indicator | RNA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 28.33 | 27.08 |
| Support Level | N/A | $1.14 |
| Resistance Level | $14.05 | $2.64 |
| Average True Range (ATR) | 0.50 | 0.15 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 0.38 | 8.00 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.